Randomized Trialhigh evidence
Safety and Anti-Inflammatory Effects of Engineered Extracellular Vesicles (ILB-202) for NF-κB Inhibition: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Trial.
Journal of extracellular vesicles·September 1, 2025·PMID 41002119
Why it mattersNF-κB is a central driver of many inflammatory and autoimmune conditions, but systemic inhibition often causes immunosuppression. This study introduces a potentially safer, targeted delivery approach using engineered extracellular vesicles, which could open new therapeutic avenues for pain and inflammation specialists.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled